PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Microbiology, G. Gennimatas General Hospital, Thessaloniki, Greece.\', \'Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece.\', \'Laboratory of Biometry, University of Thessaly, Magnesia, Greece; University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.\', \'Department of Cardiology, G. Gennimatas General Hospital, Thessaloniki, Greece.\', \'Intensive Care Unit, G. Gennimatas General Hospital, Thessaloniki, Greece.\', \'Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece; Clinical Trials Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, Greece. Electronic address: papazisg@auth.gr.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0264-410X(21)00958-010.1016/j.vaccine.2021.07.065
?:doi
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 34344551
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
?:title
  • Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all